Who
Mark Arnold Hagler
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, NovaBridge Biosciences.
In numbers
- Trades disclosed
- 4
- Buys
- 1
- Sells
- 0
- Bought
- $1.2M
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 24 Apr 2026
- Last trade
- 8 Jul 2026
- Last filed
- 10 Jul 2026
Companies traded
Activity over time
1 Apr – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Jul 2026filed 10 Jul 2026 | NBP NovaBridge Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —949,050 at $0.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | NBP NovaBridge Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —949,050 at $0.00 | filing |
| 24 Apr 2026filed 28 Apr 2026 | NBP NovaBridge BiosciencesBiotechnology | SEC FORM 4 Bought | $577K230,000 at $2.51 | filing |
| 24 Apr 2026filed 28 Apr 2026 | NBP NovaBridge BiosciencesBiotechnology | SEC FORM 4 Bought | $577K230,000 at $2.51 | filing |
News
No headline names them, or the companies they trade most, lately.